Skip to search formSkip to main contentSkip to account menu

L 743,872

Known as: L 743872, L-743,872, L-743872 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

CaspofunginCaspofungin acetate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2001
Review
2001
Update on antifungals targeted to the cell wall: focus on β-1,3-glucan synthase inhibitors
Currently available antifungal drugs for serious infections are either fungistatic and vulnerable to resistance (azoles) or… 
1999
1999
MK-0991 (Merck & Co).
  • A. GrollT. Walsh
  • IDrugs : the investigational drugs journal
  • 1999
  • Corpus ID: 25325816
Merck is developing the echinocandin-type antifungal, MK-0991 (L-743872), a beta-1,3-glucan synthesis inhibitor. It is currently… 
1998
1998
In-vitro isolation and antifungal susceptibility of amphotericin B-resistant mutants of Aspergillus fumigatus.
Aspergillus fumigatus mutants resistant to amphotericin B were selected in the laboratory following UV irradiation. A total of 18… 
Highly Cited
1997
Highly Cited
1997
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
MK-0991 (L-743,872) is a potent antifungal agent featuring long half-life pharmacokinetics. The pharmacokinetics of MK-0991… 
Highly Cited
1997
Highly Cited
1997
Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis
The in vivo activity of the Merck antifungal echinocandin drug candidate MK-0991 (L-743,872) was evaluated in mouse models of… 
Highly Cited
1997
Highly Cited
1997
Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro
Cryptococcus neoformans infections in patients with AIDS are often incurable, despite aggressive antifungal therapy. Combination… 
Highly Cited
1997
Highly Cited
1997
In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species
The in vitro activity of a new pneumocandin, L-743,872, was evaluated with 108 strains of Candida and compared with the… 
Highly Cited
1997
Highly Cited
1997
Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
L-743,872 is a broad-spectrum pneumocandin antifungal drug developed by Merck Research Co., and in the present work it was… 
Highly Cited
1997
Highly Cited
1997
Treatment of murine disseminated candidiasis with L-743,872
L-743,872 (M991), which is a pneumocandin derivative, was evaluated in a mouse model of disseminated candidiasis caused by a… 
Highly Cited
1997
Highly Cited
1997
In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.
L-733,560 and L-743,872 are water-soluble pneumocandins with potent antifungal activity. By beginning with the NCCLS M27-T method… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)